Bionano Genomics, Inc. stock is up 11.28% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 2 CALLs, 2 PUTs. 0% of analysts rate it a buy.
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping. NxClinical offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.